Published in Neurology on August 01, 1987
Involvement of the central nervous system in chronic inflammatory demyelinating polyneuropathy: a clinical, electrophysiological and magnetic resonance imaging study. J Neurol Neurosurg Psychiatry (1990) 1.87
Advances in the diagnosis, pathogenesis and treatment of CIDP. Nat Rev Neurol (2011) 1.38
Chronic dysimmune demyelinating polyneuropathy: a clinical and electrophysiological study of 93 patients. J Neurol Neurosurg Psychiatry (1996) 0.96
Myelin protein zero mutation His39Pro: hereditary motor and sensory neuropathy with variable onset, hearing loss, restless legs and multiple sclerosis. J Neurol Neurosurg Psychiatry (2006) 0.92
Cranial magnetic resonance imaging in chronic demyelinating polyneuropathy. J Neurol Neurosurg Psychiatry (1990) 0.84
Chronic inflammatory demyelinating polyneuropathy. Curr Treat Options Neurol (2013) 0.83
Multiple sclerosis and peripheral multifocal demyelinating neuropathies occurring in a same patient. J Clin Neurol (2008) 0.83
Acute severe combined demyelination. Childs Nerv Syst (1992) 0.81
Chronic inflammatory demyelinating polyradiculoneuropathy: from bench to bedside. Semin Neurol (2012) 0.80
Frequency of central lesions in polyneuropathy associated with IgM monoclonal gammopathy: an MRI, neurophysiological and immunochemical study. J Neurol Neurosurg Psychiatry (1992) 0.79
Linkage of multiple sclerosis and guillain-barre syndrome: a population-based survey in isfahan, iran. Autoimmune Dis (2012) 0.77
Multiple sclerosis and hypertrophic demyelinating neuropathy. J Neurol Neurosurg Psychiatry (1992) 0.75
Chronic inflammatory demyelinating polyneuropathy with multifocal CNS demyelination in an Afrid. J Neurol Neurosurg Psychiatry (1996) 0.75
Neuro-ophthalmological Complications of Chronic Inflammatory Demyelinating Polyradiculoneuropathy. Neuroophthalmology (2013) 0.75
The survival motor neuron protein in spinal muscular atrophy. Hum Mol Genet (1997) 4.86
Identification of proximal spinal muscular atrophy carriers and patients by analysis of SMNT and SMNC gene copy number. Am J Hum Genet (1997) 4.29
Myoblast transfer in the treatment of Duchenne's muscular dystrophy. N Engl J Med (1995) 2.96
Inclusion body myositis and myopathies. Ann Neurol (1995) 2.68
Correlating phenotype and genotype in the periodic paralyses. Neurology (2004) 2.55
Microvascular deposition of complement membrane attack complex in dermatomyositis. N Engl J Med (1986) 2.22
A novel cDNA detects homozygous microdeletions in greater than 50% of type I spinal muscular atrophy patients. Nat Genet (1995) 2.17
Dystrophin expression and somatic reversion in prednisone-treated and untreated Duchenne dystrophy. CIDD Study Group. Neurology (1991) 2.16
Clinical trial in Duchenne dystrophy. I. The design of the protocol. Muscle Nerve (1981) 2.06
Clinical investigation in Duchenne dystrophy: 2. Determination of the "power" of therapeutic trials based on the natural history. Muscle Nerve (1983) 1.99
Duchenne muscular dystrophy: patterns of clinical progression and effects of supportive therapy. Neurology (1989) 1.90
Randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy. Neurology (2001) 1.88
Chronic inflammatory demyelinating polyradiculoneuropathy. Clinical characteristics, course, and recommendations for diagnostic criteria. Arch Neurol (1989) 1.88
Effects of PMP22 duplication and deletions on the axonal cytoskeleton. Ann Neurol (1999) 1.81
The relationship of complement-mediated microvasculopathy to the histologic features and clinical duration of disease in dermatomyositis. Arch Neurol (1991) 1.81
Somatic reversion/suppression in Duchenne muscular dystrophy (DMD): evidence supporting a frame-restoring mechanism in rare dystrophin-positive fibers. Am J Hum Genet (1992) 1.81
High resolution MRI of the deep brain vascular anatomy at 8 Tesla: susceptibility-based enhancement of the venous structures. J Comput Assist Tomogr (1999) 1.79
Prednisone in Duchenne dystrophy. A randomized, controlled trial defining the time course and dose response. Clinical Investigation of Duchenne Dystrophy Group. Arch Neurol (1991) 1.78
Duchenne dystrophy: randomized, controlled trial of prednisone (18 months) and azathioprine (12 months) Neurology (1993) 1.75
Familial cerebellar ataxia with muscle coenzyme Q10 deficiency. Neurology (2001) 1.75
Identification of two point mutations and a one base deletion in exon 19 of the dystrophin gene by heteroduplex formation. Hum Mol Genet (1993) 1.67
Lack of toxicity of alpha-sarcoglycan overexpression supports clinical gene transfer trial in LGMD2D. Neurology (2008) 1.63
NT-3 promotes nerve regeneration and sensory improvement in CMT1A mouse models and in patients. Neurology (2005) 1.63
Painful sensory neuropathy: prospective evaluation using skin biopsy. Neurology (1999) 1.62
Toxic polyneuropathy due to methyl n-butyl ketone. An industrial outbreak. Arch Neurol (1975) 1.62
Intragenic telSMN mutations: frequency, distribution, evidence of a founder effect, and modification of the spinal muscular atrophy phenotype by cenSMN copy number. Am J Hum Genet (1998) 1.56
Pupil-sparing oculomotor palsies with internal carotid-posterior communicating artery aneurysms. Ann Neurol (1983) 1.55
Magnetic resonance imaging and clinical correlates of intellectual impairment in myotonic dystrophy. Arch Neurol (1989) 1.54
Kennedy's disease: a clinicopathologic correlation with mutations in the androgen receptor gene. Neurology (1993) 1.52
Immunosuppressive treatment of motor neuron syndromes. Attempts to distinguish a treatable disorder. Arch Neurol (1994) 1.52
An 11 base pair duplication in exon 6 of the SMN gene produces a type I spinal muscular atrophy (SMA) phenotype: further evidence for SMN as the primary SMA-determining gene. Hum Mol Genet (1996) 1.52
Quality improvement in neurology residency programs. Report of the Quality Improvement Committee of the Association of University Professors of Neurology. Neurology (1997) 1.49
Peripheral nerve vasculitis: immune characterization of the vascular lesions. Ann Neurol (1989) 1.46
Magnetic resonance imaging in Parkinson's disease. Arch Neurol (1990) 1.42
Toxic polyneuropathy produced by methyl N-butyl ketone. Science (1974) 1.42
Sodium channel mutations in paramyotonia congenita and hyperkalemic periodic paralysis. Ann Neurol (1993) 1.41
Long-term benefit from prednisone therapy in Duchenne muscular dystrophy. Neurology (1991) 1.40
Sodium channel mutations in acetazolamide-responsive myotonia congenita, paramyotonia congenita, and hyperkalemic periodic paralysis. Neurology (1994) 1.33
Functional MRI evidence of cortical reorganization in upper-limb stroke hemiplegia treated with constraint-induced movement therapy. Am J Phys Med Rehabil (2001) 1.33
Superficial peroneal nerve/peroneus brevis muscle biopsy in vasculitic neuropathy. Neurology (2000) 1.31
Peripheral nerve changes induced by methyl n-butyl ketone and potentiation by methyl ethyl ketone. J Neuropathol Exp Neurol (1976) 1.30
Induction of subacute murine measles encephalitis by monoclonal antibody to virus haemagglutinin. Nature (1981) 1.30
Cerebral cortical lesions in multiple sclerosis detected by MR imaging at 8 Tesla. AJNR Am J Neuroradiol (2007) 1.30
Acute inflammatory polyradiculoneuropathy following Hymenoptera stings. JAMA (1982) 1.29
Myoclonic epilepsy and ragged-red fibers with cytochrome oxidase deficiency: neuropathology, biochemistry, and molecular genetics. Ann Neurol (1989) 1.28
Duchenne muscular dystrophy: functional ischemia reproduces its characteristic lesions. Science (1971) 1.26
Fatal infantile mitochondrial myopathy and renal dysfunction due to cytochrome-c-oxidase deficiency. Neurology (1980) 1.25
Genotype-phenotype correlations of DHP receptor alpha 1-subunit gene mutations causing hypokalemic periodic paralysis. Neuromuscul Disord (1997) 1.24
Deletion and conversion in spinal muscular atrophy patients: is there a relationship to severity? Ann Neurol (1997) 1.23
Frameshift deletions of exons 3-7 and revertant fibers in Duchenne muscular dystrophy: mechanisms of dystrophin production. Am J Hum Genet (1995) 1.23
Orthopedic outcomes of long-term daily corticosteroid treatment in Duchenne muscular dystrophy. Neurology (2007) 1.21
Polyneuropathy and IgM monoclonal gammopathy: studies on the pathogenetic role of anti-myelin-associated glycoprotein antibody. Ann Neurol (1985) 1.20
Gastric hypomotility in Duchenne's muscular dystrophy. N Engl J Med (1988) 1.18
Randomized trials of dichlorphenamide in the periodic paralyses. Working Group on Periodic Paralysis. Ann Neurol (2000) 1.17
The clinical spectrum of necrotizing angiopathy of the peripheral nervous system. Ann Neurol (1985) 1.17
Increased plasma enzyme concentrations in rats with functional ischaemia of muscle provide a possible model of Duchenne muscular dystrophy. Nature (1972) 1.17
Taxol neuropathy. Electrodiagnostic and sural nerve biopsy findings. Arch Neurol (1994) 1.17
A comparison of daily and alternate-day prednisone therapy in the treatment of Duchenne muscular dystrophy. Arch Neurol (1991) 1.16
Multiple mitochondrial DNA deletions in sporadic inclusion body myositis: a study of 56 patients. Ann Neurol (1996) 1.15
Randomized, double-blind, placebo-controlled trial of albuterol in facioscapulohumeral dystrophy. Neurology (2001) 1.15
A missense mutation in the dystrophin gene in a Duchenne muscular dystrophy patient. Nat Genet (1993) 1.15
Spectrum of small mutations in the dystrophin coding region. Am J Hum Genet (1995) 1.15
Nonsystemic vasculitic neuropathy: insights from a clinical cohort. Neurology (2003) 1.14
Clinical investigation of Duchenne muscular dystrophy. Interesting results in a trial of prednisone. Arch Neurol (1987) 1.14
Acute renal failure resulting from intravenous immunoglobulin therapy. Arch Neurol (1993) 1.14
Comparison of vasoconstrictors for functional endoscopic sinus surgery in children. Laryngoscope (1992) 1.11
Relevance of genetic animal models of muscular dystrophy to human muscular dystrophies. Ann N Y Acad Sci (1979) 1.11
Positive neuropathic sensory symptoms as endpoints in diabetic neuropathy trials. J Neurol Sci (2001) 1.10
Mononuclear cell analysis of muscle biopsies in prednisone-treated and untreated Duchenne muscular dystrophy. CIDD Study Group. Neurology (1991) 1.10
The skeletal muscle binding site of antistriated muscle antibody in myasthenia gravis: an electron microscopic immunohistochemical study using peroxidase conjugated antibody fragments. J Immunol (1973) 1.07
High-resolution 3DFT MR imaging of the endolymphatic duct and soft tissues of the otic capsule. AJNR Am J Neuroradiol (1991) 1.06
Facioscapulohumeral muscular dystrophy (FSHD): design of natural history study and results of baseline testing. FSH-DY Group. Neurology (1994) 1.06
High resolution MRI of the deep gray nuclei at 8 Tesla. J Comput Assist Tomogr (1999) 1.06
Modification by L-dopa of a case of progressive supranuclear palsy. With evidence of defective cerebral dopamine metabolism. Lancet (1970) 1.03
Novel and recurrent mutations in lamin A/C in patients with Emery-Dreifuss muscular dystrophy. Am J Med Genet (2001) 1.02
Clinical investigation of Duchenne muscular dystrophy. A methodology for therapeutic trials based on natural history controls. Arch Neurol (1987) 1.02
Mapping the facioscapulohumeral muscular dystrophy gene is complicated by chromsome 4q35 recombination events. Nat Genet (1993) 1.01
Azathioprine toxicity in neuromuscular disease. Neurology (1986) 1.01
Treatment of stiff-man syndrome with intravenous immunoglobulin. Neurology (1994) 1.00
Autonomic impairment in painful neuropathy. Neurology (2001) 1.00
Proximal myopathy induced by 5-HT-imipramine simulates Duchenne dystrophy. Nature (1974) 0.99
Monoclonal antibodies against five structural components of measles virus. II. Characterization of five cell lines persistently infected with measles virus. Arch Virol (1985) 0.99